References
- GomesPJTrends in prevalence and treatment of ocular allergyCurr Opin Allergy Clin Immunol201414545145625115683
- CalongeMClassification of ocular atopic/allergic disorders and conditions: an unsolved problemActa Ophthalmol Scand Suppl1999228101310337423
- BoniniSAtopic keratoconjunctivitisAllergy200459suppl 78717315245362
- FriedlaenderMHOcular allergyCurr Opin Allergy Clin Immunol201111547748221822130
- ChigbuDIThe pathophysiology of ocular allergy: a reviewCont Lens Anterior Eye200932131518805042
- AzariAABarneyNPConjunctivitis: a systematic review of diagnosis and treatmentJAMA2013310161721172924150468
- RidoloEMontagniMCaminatiMSennaGIncorvaiaCCanonicaGWEmerging drugs for allergic conjunctivitisExpert Opin Emerg Drugs201419229130224661261
- YanniJMStephensDJMillerSTThe in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agentJ Ocul Pharmacol Ther19961243894008951675
- BabaATachiMMaruyamaYKazamaIOlopatadine inhibits exocytosis in rat peritoneal mast cells by counteracting membrane surface deformationCell Physiol Biochem201535138639625591779
- BerdyGJSpanglerDLBenschGBerdySSBrusattiRCA comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge modelClin Ther200022782683310945509
- SpanglerDLBenschGBerdyGJEvaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge modelClin Ther20012381272128011558863
- AbelsonMBGomesPJVogelsonCTEffects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitisCurr Med Res Opin200521568369115969867
- VogelsonCTAbelsonMBPasquineTPreclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administrationAllergy Asthma Proc2004251697515055565
- McLaurinENarvekarAGomesPAdewaleATorkildsenGPhase 3 randomized double-masked study of efficacy and safety of once-daily 0.77% olopatadine hydrochloride ophthalmic solution in subjects with allergic conjunctivitis using the conjunctival allergen challenge modelCornea201534101245125126266427
- TorkildsenGNarvekarABergmannMEfficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge modelClin Ophthalmol201591703171326392751
- IyerGRCasonMMWombleSWLiGChastainJEOcular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbitsJ Ocul Pharmacol Ther201531420421025775192
- BieloryLAllergic and immunologic disorders of the eye. Part II: ocular allergyJ Allergy Clin Immunol200010661019103211112882
- AsherMIMontefortSBjorkstenBISAAC Phase Three Study GroupWorldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveysLancet2006368953773374316935684
- Aït-KhaledNPearceNAndersonHRISAAC Phase Three Study GroupGlobal map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase ThreeAllergy200964112314819132975
- RosarioNBieloryLEpidemiology of allergic conjunctivitisCurr Opin Allergy Clin Immunol201111547147621785348
- LeonardiABogackaEFauquertJLOcular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surfaceAllergy201267111327133722947083
- MallolJCraneJvon MutiusEThe International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesisAllergol Immunopathol (Madr)2013412738522771150
- TsunooMMomomuraSMasuoMIizukaHPhase 1 clinical study on KW-4679, an antiallergic drug: safety and pharmacokinetics in the single and repeated administration study in healthy subjectsKiso To Rinsho19952918
- LichtensteinSJPasquineTAEdwardsMRWellsDTGrossRDRobertsonSMSafety and tolerability of olopatadine 0.2% in children and adolescentsJ Ocul Pharmacol Ther200723436637117803435
- Food and Drug AdministrationPazeo Labeling2015 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206276Orig1s000SumR.pdfAccessed February 8, 2017
- EndreLDuBuskeLMThe safety of olopatadine in children with seasonal allergic conjunctivitisJ Allergy Clin Immunol2009123suppl S128489